Ignite Creation Date:
2024-05-06 @ 2:37 PM
Last Modification Date:
2024-10-26 @ 1:34 PM
Study NCT ID:
NCT04375046
Status:
UNKNOWN
Last Update Posted:
2021-06-09
First Post:
2020-05-01
Brief Title:
Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2
Sponsor:
Kafrelsheikh University
Organization:
Kafrelsheikh University
Organization Data
Organization:
Kafrelsheikh University
Class:
OTHER
Study ID:
proposed by Mahmoud kazazzaz
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Kafrelsheikh University
Lead Sponsor Class:
OTHER
Responsible Party:
Mahmoud Ramadan mohamed Elkazzaz
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Kafrelsheikh University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine The First Hospital of Jilin University China | UNKNOWN |